
Sun Pharma's baldness treatment, Leqselvi (deuruxolitinib), has received US FDA approval for severe alopecia areata. Acquired through the $576 million purchase of Concert Pharmaceuticals in January 2023, the drug is a potential game-changer in alopecia treatment. Deuruxolitinib, a JAK inhibitor, offers new hope for patients and will be marketed exclusively by Sun Pharma for five years. Shares surged following the announcement.
Like
Save
Share